Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société IPSEN
05:54aIPSEN : A new language inviting you to understand more about the rare disease co..
PU
02/22IPSEN : announces new data from the Phase II CLARINET FORTE study which demonstr..
AQ
02/22IPSEN : Announces New Data from the Phase II CLARINET FORTE Study Which Demonstr..
BU
02/11IPSEN : FY2020 financial results
PU
02/11IPSEN : delivered sales growth and margin expansion in 2020 – Focused on e..
PU
02/11IPSEN : Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executi..
BU
02/09IPSEN : New data from pivotal Phase III CheckMate -9ER trial of Cabometyx in com..
AQ
02/08IPSEN : New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in co..
PU
02/08IPSEN : New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx® in Co..
BU
02/08Ipsen to showcase commitment to going beyond traditional outcome measures for..
AQ
02/05IPSEN : to Showcase Commitment to Going Beyond Traditional Outcome Measures for ..
BU
01/21IPSEN : appoints Gwenan White as Executive Vice President Communications and Pub..
AQ
01/20IPSEN : Appoints Gwenan White as Executive Vice President, Communications and Pu..
BU
01/19IPSEN : Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
BU
01/18IPSEN : TOXINS 2021, new analyses of pivotal Phase III trial data highlight long..
AQ
01/15TOXINS 2021 : New analyses of pivotal Phase III trial data highlight long durati..
BU
01/14IPSEN : Why 2021 is the year for R&D progress
PU
2020IPSEN : and the fight against corruption
PU
2020IPSEN : receives FDA Fast Track designation for investigational irinotecan lipos..
AQ
2020IPSEN : new strategic priorities unveiled at virtual Capital Markets Day event
PU
2020IPSEN : Highlights New Strategic Priorities and Provides Mid-Term Financial Outl..
BU
2020IPSEN : receives FDA Fast Track designation for investigational irinotecan lipos..
PU
2020EACD 2020 : How the use of functional assessments in clinical trials provides me..
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/20..
BU
2020IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
AQ
2020IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
2020IPSEN : announces sales growth over the first 9 months of 2020
PU
2020IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
PU
2020IPSEN : Delivers Sales Growth in the First Nine Months of 2020 Despite the Impac..
BU
2020IPSEN : Disclosure of Transactions in Own Shares between 10/12/2020 and 10/16/20..
BU
2020IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
2020BREAST CANCER AWARENESS MONTH : raising awareness with inspirational patient sto..
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 10/05/2020 and 10/09/20..
BU
2020IPSEN : to present 12 abstracts at the 11th World Congress for Neurorehabilitati..
AQ
2020IPSEN : to Present 12 Abstracts at the 11th World Congress for Neurorehabilitati..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 09/28/2020 and 10/02/20..
BU
2020IPSEN : Disclosure of transactions in own shares between 09/21/2020 and 09/25/20..
BU
2020IPSEN : appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Bus..
AQ
2020IPSEN : announces the appointment of new EVP Business Development
PU
2020IPSEN : appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Bus..
PU
2020IPSEN : Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Bus..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 09/14/2020 and 09/18/20..
BU
2020IPSEN GROUP : - ESMO 2020, Cabometyx in combination with Opdivo demonstrates sig..
AQ
2020ESMO 2020 : Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) de..
PU
2020ESMO 2020 : Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) De..
BU
2020ESMO 2020 : Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of ..
BU
2020ESMO 2020 : Phase II CLARINET FORTE results show increasing dose frequencies of ..
PU
2020PUTTING OUR PURPOSE TO THE TEST : what we and the community are learning from ou..
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 09/07/2020 and 09/11/20..
BU
2020IPSEN : showcases commitment to patient-centric advances in oncology with record..
AQ
2020IPSEN : Showcases Commitment to Patient-centric Advances in Oncology With Record..
BU
2020IPSEN : to Present New Insights at ASBMR for Potential Treatment of Ultra-rare D..
BU
2020IPSEN : to present new insights at ASBMR for potential treatment of ultra-rare d..
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 31/08/2020 and 04/09/20..
BU
2020IPSEN : Executive Leadership Team Announcement
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 24/08/2020 And 28/08/20..
BU
2020IPSEN : to present results from MOVE, the first global Phase III trial in fibrod..
AQ
2020IPSEN : Disclosure of Transactions in Own Shares Between 17/08/2020 and 21/08/20..
BU
2020IPSEN : to Present Results From MOVE, the First Global Phase III Trial in Fibrod..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 10/08/2020 and 14/08/20..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 03/08/2020 and 07/08/20..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 27/07/2020 and 31/07/20..
BU
2020IPSEN : announces 3.1% Group Sales Growth, reinstates 2020 guidance
PU
2020IPSEN : Presents Its Half Year 2020 Results and Reinstates Guidance for Full Yea..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 20/07/2020 and 24/07/20..
BU
2020IPSEN : Half Year 2020 Sales Conference Call – Thursday, July 30, 2020
PU
2020IPSEN : Disclosure of Transactions in Own Shares Between 13/07/2020 And 17/07/20..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 06/07/2020 And 10/07/20..
BU
2020IPSEN : Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
BU
2020IPSEN : Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the T..
BU
2020IPSEN : Disclosure of Transactions in Own Shares Between 29/06/2020 And 03/07/20..
BU
2020IPSEN : presents Phase I/II clinical data evaluating liposomal irinotecan as an ..
AQ
2020IPSEN : Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus ..
BU
2020IPSEN : presents Phase I/II clinical data evaluating liposomal irinotecan (Onivy..
BU
2020IPSEN : David Loew joins Ipsen as CEO
PU
1  2  3  4  5  6  7Next
Upcoming event on IPSEN